Novartis multiple sclerosis drug Fengomode gets FDA approval to go on the market

recently, Novart
is multi-
drug(http://Fengomode was approved for marketing by the NationalDrug(http://Regulatory Authority, the second new
drug (http://) approved in China for oral multiple sclerosis, following Sanofitrifluomine in July 2018About FingomedoreFengomode is the world's first available oral therapy to reduce the frequency of MS recurrence, first approved by theFDA(http://in 2010/9/21, reaching an all-time high of $3.341 billion in annual sales in 2018In May 2018, Gilenya was approved for the treatment of multiple sclerosis (MS) in children and adolescents aged 10 and over, becoming the first drug to treat MS in children 　　Fingomod is a neuromothane 1-phosphate receptor regulator that was originally isolated from the fungus Sinclair worm and its close relative, the winter worm summer grass, with strong immunosuppressive activity 　　The of long-term clinical trials (http:// shows that Gilenya's ease of use improves patient compliance and ultimately improves long-term prognosis 　　On March 26 this year, Fingomode's upgraded product
(http:// Mayzent (siponimod, sinimod) was approved by the FDA for the treatment of adult recurrent multiple sclerosis, including clinically isolated syndrome, recurrent recurrent multiple sclerosis, active secondary progressive multiple sclerosis, priced at $8800/year 　　The listing application for siponimod in China (JXHS1900029) is also accepted in 2019/2/18 and is currently in the review process health
in November, the FDA issued a safety warning to Fingomode, saying that after patients with multiple sclerosis were treated with the Novartis multiple sclerosis drug Gilenya, a suspension could lead to serious illness or even permanent disability 　　Therefore, the FDA recommends that patients be informed of the risk of disability of the drug before using Gilenya and observe adverse reactions after discontinuation The good news is that in the past June, Novartis successfully thwarted the threat of patent (http:// of the of Pharmaceuticals (http:// (see: Gilenya, Novartis's multiple sclerosis drug)